Spark Stands By $1M Or More Price Possibility For Luxturna
Executive Summary
Management did not disclose the pricing strategy for the gene therapy for blindness during its third quarter financial update, but did confirm that the value of the therapy is in excess of $1m per patient.
You may also be interested in...
The First US Gene Therapy Maker Innovates On Pricing And Reimbursement
Spark priced the gene therapy Luxturna for inherited blindness at $850,000 for treatment of both eyes, below the $1m price some expected, and revealed pioneering market access plans. CEO Jeffrey Marrazzo and Harvard Pilgrim's Michael Sherman talked with Scrip about the details.
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Spark's gene therapy for patients with an inherited form of blindness will be available in the US late in the first quarter, but on the big question – whether it will cost $1m for the one-time treatment – Spark would not say.
$1M For Luxturna? ICER Says Big Discount Needed To Be Cost Effective
Luxturna, a one-time treatment for a rare inherited form of blindness, would not be cost-effective at the $1m price level that has been suggested as a possibility, based on ICER's thresholds. But the small patient population would keep it from triggering ICER's US budget spending threshold.